United States· US:50242-109_e8a259ac-2a09-4026-823c-f23cbcba6a2b
Rituxan Hycela
A medicinal product containing rituximab; hyaluronidase (human recombinant), registered in United States by Genentech, Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- RITUXIMAB; HYALURONIDASE (HUMAN RECOMBINANT)
- Manufacturer
- Genentech, Inc.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1150242-109-01
- ndc1150242109011 VIAL, SINGLE-DOSE in 1 CARTON (50242-109-01) / 13.4 mL in 1 VIAL, SINGLE-DOSE
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/da06d156-f89e-41fd-979e-bd8649643116 GET /v1/drugs/da06d156-f89e-41fd-979e-bd8649643116?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "120; 2000",
"substance": "RITUXIMAB; HYALURONIDASE (HUMAN RECOMBINANT)",
"productndc": "50242-109",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL; U/mL",
"application_number": "BLA761064",
"marketing_category": "BLA"
}See everything about rituximab; hyaluronidase (human recombinant).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.